Skip to main content
SpringerLink
Log in

The relationship between long-term proton pump inhibitor therapy and skeletal frailty

  • Mini Review
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Proton pump inhibitors (PPIs) are a commonly prescribed class of medications. Their use has been associated with an increased rate of fractures, most notably hip fractures. However, there does not seem to be a clear association between PPI use and bone mineral density measurements, assessed by dual X-ray absorptiometry. The mechanism by which PPI use increases the risk of fractures remains unclear. This review will summarize the current evidence on this topic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. M.L. Schubert, D.A. Peura, Control of gastric acid secretion in health and disease. Gastroenterology 134(7), 1842–1860 (2008)

    Article  CAS  PubMed  Google Scholar 

  2. A.B. Thomson et al., Safety of the long-term use of proton pump inhibitors. World J. Gastroenterol. 16(19), 2323–2330 (2010)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. S. Dial et al., Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294(23), 2989–2995 (2005)

    Article  CAS  PubMed  Google Scholar 

  4. R.J. Laheij et al., Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292(16), 1955–1960 (2004)

    Article  CAS  PubMed  Google Scholar 

  5. M.D. Howell et al., Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch. Intern. Med. 170(9), 784–790 (2010)

    Article  PubMed  Google Scholar 

  6. A. Deshpande et al., Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin. Gastroenterol. Hepatol. 10(3), 225–233 (2012)

    Article  CAS  PubMed  Google Scholar 

  7. N.R. Rozgony et al., Vitamin B(12) deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin nasal spray be beneficial? J. Nutr. Elder 29(1), 87–99 (2010)

    Article  PubMed  Google Scholar 

  8. K.L. Insogna, The effect of proton pump-inhibiting drugs on mineral metabolism. Am. J. Gastroenterol. 104(Suppl 2), S2–S4 (2009)

    Article  CAS  PubMed  Google Scholar 

  9. H. Koop, Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment. Pharmacol. Ther. 6(4), 399–406 (1992)

    Article  CAS  PubMed  Google Scholar 

  10. S.A. Wainwright et al., Hip fracture in women without osteoporosis. J. Clin. Endocrinol. Metab. 90(5), 2787–2793 (2005)

    Article  CAS  PubMed  Google Scholar 

  11. S.R. Cummings et al., Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N. Engl. J. Med. 332(12), 767–773 (1995)

    Article  CAS  PubMed  Google Scholar 

  12. S.P. Marcuard, L. Albernaz, P.G. Khazanie, Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann. Intern. Med. 120(3), 211–215 (1994)

    Article  CAS  PubMed  Google Scholar 

  13. J.R. Lewis et al., Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J. Bone Miner. Res. 29(11), 2489–2497 (2014)

    Article  PubMed  Google Scholar 

  14. E. Salgueiro et al., Safety profile of proton pump inhibitors according to the spontaneous reports of suspected adverse reactions. Int. J. Clin. Pharmacol. Ther. 44(11), 548–556 (2006)

    Article  CAS  PubMed  Google Scholar 

  15. B.M. Kuschel, L. Laflamme, J. Moller, The risk of fall injury in relation to commonly prescribed medications among older people-a Swedish case–control study. Eur. J. Public Health (2014). doi:10.1093/eurpub/cku120

  16. K. Zhu et al., ‘Timed up and go’ test and bone mineral density measurement for fracture prediction. Arch. Intern. Med. 171(18), 1655–1661 (2011)

    Article  PubMed  Google Scholar 

  17. S.L. Gray et al., Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch. Intern. Med. 170(9), 765–771 (2010)

    Article  PubMed Central  PubMed  Google Scholar 

  18. L.E. Targownik et al., Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138(3), 896–904 (2010)

    Article  CAS  PubMed  Google Scholar 

  19. D.H. Solomon et al., Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. J. Bone Miner. Res. 30(2), 232–239 (2014)

    Article  Google Scholar 

  20. G. Ioannidis et al., Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 181(5), 265–271 (2009)

    Article  PubMed Central  PubMed  Google Scholar 

  21. Y.X. Yang et al., Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24), 2947–2953 (2006)

    Article  CAS  PubMed  Google Scholar 

  22. B. Abrahamsen, P. Vestergaard, Proton pump inhibitor use and fracture risk—effect modification by histamine H1 receptor blockade. Observational case–control study using national prescription data. Bone 57(1), 269–271 (2013)

    Article  CAS  PubMed  Google Scholar 

  23. J. Ding et al., The relationship between proton pump inhibitor adherence and fracture risk in the elderly. Calcif. Tissue Int. 94(6), 597–607 (2014)

    Article  CAS  PubMed  Google Scholar 

  24. L.M. Moberg et al., Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas 78(4), 310–315 (2014)

    Article  CAS  PubMed  Google Scholar 

  25. J. Lee et al., A population-based case–control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J. Gastroenterol. 48(9), 1016–1022 (2013)

    Article  CAS  PubMed  Google Scholar 

  26. D. Prieto-Alhambra et al., Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J. Bone Miner. Res. 29(1), 268–274 (2014)

    Article  CAS  PubMed  Google Scholar 

  27. J.A. Kanis et al., FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19(4), 385–397 (2008)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. P. Vestergaard, L. Rejnmark, L. Mosekilde, Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif. Tissue Int. 79(2), 76–83 (2006)

    Article  CAS  PubMed  Google Scholar 

  29. F. de Vries et al., Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos. Int. 20(12), 1989–1998 (2009)

    Article  CAS  PubMed  Google Scholar 

  30. E.W. Yu et al., Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am. J. Med. 124(6), 519–526 (2011)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. D.P. Kiel et al., Health care utilization and functional status in the aged following a fall. Med. Care 29(3), 221–228 (1991)

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

Arthur Lau: Honorariums/Consultations: Amgen, Abbvie, Roche, UCB, Celgene; Stocks: None to declare. Jonathan D. Adachi: Honorariums/Consultations: Amgen, Merck Frost Canada, Eli Lilly, Warner Chilcott; Stocks: None to declare. Michael Tomizza: None to declare. Matthew Wong Pack: None to declare. Alexandra Papaioannou: Honorariums/Consultations: Amgen, Merck Frost Canada, Eli Lilly, Warner Chilcott, Novartis.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Medicine, McMaster University, Hamilton, Canada

    Arthur N. Lau & Jonathan D. Adachi

  2. Faculty of Health Sciences, McMaster University, Hamilton, Canada

    Michael Tomizza & Matthew Wong-Pack

  3. Division of Geriatrics, Department of Medicine, McMaster University, Hamilton, Canada

    Alexandra Papaioannou

Authors
  1. Arthur N. Lau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Tomizza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew Wong-Pack
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexandra Papaioannou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jonathan D. Adachi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arthur N. Lau.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lau, A.N., Tomizza, M., Wong-Pack, M. et al. The relationship between long-term proton pump inhibitor therapy and skeletal frailty. Endocrine 49, 606–610 (2015). https://doi.org/10.1007/s12020-015-0576-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-015-0576-z

Keywords

Search

Navigation